[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA55142A - Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation - Google Patents

Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation

Info

Publication number
MA55142A
MA55142A MA055142A MA55142A MA55142A MA 55142 A MA55142 A MA 55142A MA 055142 A MA055142 A MA 055142A MA 55142 A MA55142 A MA 55142A MA 55142 A MA55142 A MA 55142A
Authority
MA
Morocco
Prior art keywords
amino
triazolopyrazine
triazolopyrimidine
pharmaceutical compositions
receptor antagonist
Prior art date
Application number
MA055142A
Other languages
English (en)
Inventor
Amjad Ali
Zachary G Brill
Jared Cumming
Duane Demong
Qiaolin Deng
Thomas H Graham
Rongze Kuang
Yeon-Hee Lim
Christopher W Plummer
Duque Jenny Lorena Rico
Huijun Wang
Yonglian Zhang
Kake Zhao
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA55142A publication Critical patent/MA55142A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA055142A 2018-11-20 2019-11-15 Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation MA55142A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862769843P 2018-11-20 2018-11-20

Publications (1)

Publication Number Publication Date
MA55142A true MA55142A (fr) 2022-02-23

Family

ID=70774154

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055142A MA55142A (fr) 2018-11-20 2019-11-15 Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation

Country Status (11)

Country Link
US (1) US20210395255A1 (fr)
EP (1) EP3883575A4 (fr)
JP (1) JP2022507734A (fr)
KR (1) KR20210093964A (fr)
CN (1) CN113015530A (fr)
AU (1) AU2019383948A1 (fr)
BR (1) BR112021009078A8 (fr)
CA (1) CA3119774A1 (fr)
MA (1) MA55142A (fr)
MX (1) MX2021005839A (fr)
WO (1) WO2020106558A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112700A1 (fr) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. Dérivés amino triazolo quinazoline 9-substitués utiles en tant qu'antagonistes du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
JP2022545923A (ja) * 2019-08-26 2022-11-01 インサイト・コーポレイション A2a/a2b阻害剤としてのトリアゾロピリミジン
WO2023201267A1 (fr) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Polythérapie pour le traitement de cancers exprimant trop-2

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU743910B2 (en) * 1997-03-24 2002-02-07 Kyowa Hakko Kirin Co., Ltd. {1,2,4}triazolo{1,5-c}pyrimidine derivatives
JPWO2003028732A1 (ja) * 2001-09-28 2005-01-13 協和醗酵工業株式会社 受容体拮抗剤
PE20030739A1 (es) * 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
WO2003068776A1 (fr) * 2002-02-15 2003-08-21 Kyowa Hakko Kogyo Co., Ltd. Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine
DK2206517T3 (da) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer
US20060058320A1 (en) * 2002-09-24 2006-03-16 Kyowa Hakko Kogyo Co., Ltd. [1,2,4] Triazolo[1,5-c]pyrimidine derivatives
EP1576014B1 (fr) 2002-12-23 2011-06-29 Wyeth LLC Anticorps anti pd-1 et leurs utilisations
EP2270051B1 (fr) 2003-01-23 2019-05-15 Ono Pharmaceutical Co., Ltd. Anticorps spécifiques de PD-1 et CD3 humains
WO2004092177A1 (fr) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines et procedes de preparation et d'utilisation ce celles-ci
CA3151350A1 (fr) 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
DE102008023801A1 (de) * 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
JP2012510429A (ja) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Pd−1アンタゴニストおよびその使用方法
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도
DK4209510T5 (da) 2008-12-09 2024-07-22 Hoffmann La Roche Anti-pd-l1-antistoffer og deres anvendelse til at fremme t-cellefunktion
EP2504028A4 (fr) 2009-11-24 2014-04-09 Amplimmune Inc Inhibition simultanée de pd-l1/pd-l2
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック, インコーポレイテッド Pd−1軸結合アンタゴニストとmek阻害剤を使用する癌の治療方法
WO2017223414A1 (fr) * 2016-06-24 2017-12-28 Incyte Corporation Composants hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-y
PL3611174T3 (pl) 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
CN109535161B (zh) 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
CR20200441A (es) 2018-02-27 2021-03-15 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b

Also Published As

Publication number Publication date
EP3883575A1 (fr) 2021-09-29
CA3119774A1 (fr) 2020-05-28
CN113015530A (zh) 2021-06-22
MX2021005839A (es) 2021-07-15
BR112021009078A2 (pt) 2021-08-10
BR112021009078A8 (pt) 2023-02-07
KR20210093964A (ko) 2021-07-28
US20210395255A1 (en) 2021-12-23
JP2022507734A (ja) 2022-01-18
EP3883575A4 (fr) 2022-06-15
WO2020106558A1 (fr) 2020-05-28
AU2019383948A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
MA49753A (fr) Agents de liaison se liant à pd-l1 et cd137 et leur utilisation
IL279015A (en) Anti-interleukin-17A antibody, its pharmaceutical preparation and its use
MA54298A (fr) Dérivés amino triazolo quinazoline 9-substitués utiles en tant qu'antagonistes du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
MA52245A (fr) Promédicaments d'antagonistes de c5ar bicycliques fusionnés
MA50663A (fr) Formulations stables d'anticorps anti-récepteur de mort programmée 1 (pd-1) et leur utilisation
MA49270A (fr) Récepteurs de liaison à l'antigène améliorés
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA55142A (fr) Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
MA52285A (fr) Anticorps multispécifiques et leur utilisation
MA50175A (fr) Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
MA54395A (fr) Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
MA52249A (fr) Antagonistes de l'intégrine humaine (alpha4) (beta7)
IL279152A (en) Melanocortin subtype-2 receptor antagonists and uses thereof
IL277144A (en) Adenosine receptor antagonists and uses thereof
EP3883576A4 (fr) Composés amino-triazolopyrimidine et amino-triazolopyrazine substitués utilisés en tant qu'antagonistes de récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
MA53218A (fr) Antagonistes de l'intégrine
EP3594221A4 (fr) Antagoniste du récepteur gpr84 et son utilisation
MA52098A (fr) Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
WO2015116856A3 (fr) Antagonistes du récepteur x de farnésoïde
MA55015A (fr) Formulations pharmaceutiques
MA42527A (fr) Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
IL276290A (en) Heteroaryl compounds, their pharmaceutical preparations and their medical use
MA49524A (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof